Evercore ISI Group Maintains In-Line on AN2 Therapeutics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko maintains an In-Line rating on AN2 Therapeutics (NASDAQ:ANTX) but lowers the price target from $7 to $2.
May 16, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Evercore ISI Group has maintained an In-Line rating on AN2 Therapeutics but significantly lowered the price target from $7 to $2.
The significant reduction in the price target from $7 to $2 by Evercore ISI Group suggests a negative outlook on AN2 Therapeutics' future performance. This is likely to result in a short-term decline in the stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100